NAT2 and tuberculosis: Studies focusing on NAT2 pharmacogenomic heterogeneity of geographically diverse TB populations of a high TB burden country like India are sparse, leaving gaps in understanding region-specific allelic variant frequency and variations and their potential implications such as in the occurrence of AT-DILI.